News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Biovail Corporation Settles Cardizem Case with $22.2 Million Fine
September 15, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- A U.S. unit of Canadian drugmaker Biovail Corp has pleaded guilty to conspiracy and kickback charges, ending a case over its Cardizem hypertension drug, the U.S. Justice Department said on Monday.
Twitter
LinkedIn
Facebook
Email
Print
Legal
MORE ON THIS TOPIC
Government
Spending Bill Clears House, Keeping Priority Review Voucher Hopes Alive
January 23, 2026
·
3 min read
·
Tristan Manalac
Vaccines
ACIP Chair Questions Polio Vaccines, Values Individual Choice Over Public Benefit
January 23, 2026
·
2 min read
·
Tristan Manalac
Manufacturing
FDA Sets Feb. 1 Launch Date for PreCheck Pilot To Strengthen Domestic Supply Chain
January 22, 2026
·
2 min read
·
Nick Paul Taylor
Vaccines
‘Almost Like a Religion’: Pfizer CEO Slams RFK Jr.’s ‘Anti-Science’ Vaccine Policies
January 22, 2026
·
2 min read
·
Tristan Manalac